GlobeNewswire

DNAtix, the Genetics Blockchain Company, Introduces Complete Genome Sequencing Pilot and Announces Token Sale

Dela

Anonymous DNA Testing, Transfer, Storage with Total Control of Personal Data

 

AMSTERDAM, Netherlands, June 27, 2018 (GLOBE NEWSWIRE) -- Digital DNAtix Ltd., the genetics blockchain company, today announced the pilot of a breakthrough blockchain-based infrastructure and ecosystem for anonymous genetic testing, services and research. DNAtix is the first company to successfully transfer a genetic sequence over the Ethereum Blockchain. The DNAtix genetics ecosystem links individual users in the search of health solutions, or answers to ancestral questions, with products and services that fit their needs. DNAtix is also developing a dedicated Token - the DNATIX token - that will be integrated into the use of its DNAtix genetic platform.

"DNAtix is solving the privacy issue once and for all for testing highly sensitive DNA data with the first infrastructure blockchain ecosystem solution for anonymous genetic services," said Ofer A. Lidsky the CEO & CTO of the DNAtix. "Consumers, healthcare institutions, research centers, clinics, genetic counselors and others interested in using, testing, or gathering DNA data can now connect, work together for better health solutions and feel confident in sharing their genetic information."

Anyone can anonymously upload partial and/or full genome sequences onto the DNAtix platform; contributors own their genomic data and use it to make informed decisions.

Technology Breakthrough: An entire genetics ecosystem on the blockchain
Opening the door for advancements in research, new treatments, and cutting-edge personalized and preventive medicine, DNAtix's D2C platform provides full genome testing and access to services and solutions on the Blockchain and allows researchers to use anonymous DNA, stored on the DNAtix infrastructure, to create tests, do research and design new treatments.

In order to better leverage the emerging infrastructure and potential of blockchain genetic storage, DNAtix has developed and freely releases its compression algorithm for the mutual betterment of the field; Thus far, DNA storage efficiency has been increased by 300%.
GitHub repository: https://github.com/DNAtix/DNAtix-DNA-Compression-Tool

The DNATIX Token
DNAtix is in the private sale stage of its token to fund the delivery of anonymous genetic services at an affordable price point. The DNAtix token has smart contracts built into it enabling -for the first time- the anonymous and secure analysis, transfer, and storage of DNA sequences. The DNAtix wallet will facilitate anonymous payment for a wide range of genetic services. For more information and purchase instructions about DNAtix token sale, email:  info@dnatix.com.

SPEAKING: DNAtix AT BLOCKCHAIN EXPO EUROPE  
Ofer A. Lidsky will be presenting twice at Blockchain Expo Europe:

· Track:  Developing Blockchain Applications
· Day/Time:  Day 1 (27 June) 14:40 - 14:50
· Title: Introducing new developments 2 (When Blockchain Meets Genetics)
   
· Track: Blockchain Technologies
· Day/Time: Day 2 (28 June) 09:40 - 10:20
· Keynote Panel: What does the future hold for Blockchain technology - where do we think we will be in 2030?

More information: https://blockchain-expo.com/europe/speaker/senior-representative-dnatix/

ABOUT DNAtix
DNAtix, a cutting-edge genetics and blockchain company, is building the infrastructure for the world's genetic blockchain ecosystem where researchers, hospitals, developers, clinicians and others will develop next generation, decentralized genetics applications and health management solutions. DNAtix is also delivering a direct-to-consumer platform that offers anonymous and encrypted genome sequencing and genetic services, including digitized DNA analysis, storage and transfer.  The DNAtix genetics ecosystem is a place where consumers and the industry can meet to share genetic data in a more transparent, accessible, applicable and secured manner. DNAtix is developing the future ecosystem for Genetics which is Blockchain based and includes cutting edge new innovative ideas and technologies. With a first successful proof of concept already completed for transferring a DNA sequence over the Ethereum blockchain DNAtix is leading the world of Genetic blockchain.  www.dnatix.com 

Media Contact: 
Heidi Groshelle 
Groshelle Communications 
heidi@groshelle.com 
415.307.1380

A video accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/9f9e2aca-e48d-4d99-a20f-860e3995878b 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DNAtix via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum